The Predictive Value of Peak Cough Flow for Endotracheal Extubation of Patients After Craniotomy
Launched by BEIJING TIANTAN HOSPITAL · Jun 26, 2019
Trial Information
Current as of August 14, 2025
Completed
Keywords
ClinConnect Summary
The objection of this study is to evaluate the preditive value of PCF for endotracheal extubation in patients undergoing craniotomy. For patients who met the inclusion criteria, the PCF value will be measured before the removal of entracheal tubes, and the predictive value of PCF will be evaluated by ROC curves, as will as the cut-off value of PCF.
According to state of consciousness, patients will be grouped as consciousness and unconsciousness group, and the predictive value of PCF for endotracheal extubation will be evaluated seprately in both groups. For patients with disturbance of co...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age ≥ 18 years
- • Post- craniotomy
- • ICU LOS ≥ 24h
- Exclusion Criteria:
- • no extubation attempt during the ICU stay;
- • underwent tracheostomy without extubation attempt;
- • pregnant or lactating women;
- • enrolled in other clinical trials;
- • declined to participate in the study.
About Beijing Tiantan Hospital
Beijing Tiantan Hospital, affiliated with Capital Medical University, is a leading medical institution in China renowned for its expertise in neurology, neurosurgery, and various other specialties. As a prominent clinical trial sponsor, the hospital is committed to advancing medical research and improving patient outcomes through innovative studies. With a focus on high-quality clinical trials, Beijing Tiantan Hospital adheres to rigorous ethical standards and regulatory requirements, fostering collaboration with academic institutions and industry partners to facilitate the development of cutting-edge therapies and interventions. Its state-of-the-art facilities and experienced research team enable the hospital to play a pivotal role in the global medical research landscape.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Beijing, Beijing, China
Patients applied
Trial Officials
Jianxin Zhou, MD
Study Director
Beijing Tian Tan Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials